Clinical Trial Update: An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis [Phase 2]

View source ↗

Summary

An open-label Phase 2 study evaluating ML-007C-MA for psychosis in adults with Alzheimer's disease; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ML-007C-MA

Snippet

Sponsor: MapLight Therapeutics | Conditions: Psychosis Associated With Alzheimer's Disease | Phase 2 | Status: RECRUITING